Corcept Therapeutics Inc
SWB:HTD

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
SWB:HTD
Watchlist
Price: 49.34 EUR 1.79% Market Closed
Market Cap: 3.4B EUR
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

34.4
Current
19.8
Median
16.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
34.4
=
Enterprise Value
4.9B USD
/
EBIT
143.4m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
Corcept Therapeutics Inc
SWB:HTD
Average EV/EBIT: 1 813.6
34.4
73%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.2
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.6
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.9
9%
1.7
US
Merck & Co Inc
NYSE:MRK
12.5
98%
0.1
CH
Roche Holding AG
SIX:ROG
11.9
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
253.9
32%
7.9
CH
Novartis AG
SIX:NOVN
13.2
17%
0.8
US
Pfizer Inc
NYSE:PFE
15.9
19%
0.8

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
29.2
2-Years Forward
EV/EBIT
20.3
3-Years Forward
EV/EBIT
8.8